Atrix, Elan partner
Atrix Laboratories Inc. (Nasdaq: ATRX), a Fort Collins-based pharmaceutical company, has formed a joint venture with Elan Corp. (NYSE: ELN) to advance the testing of a new pain product for cancer patients. Through their collaborative effort, Transmucosal Technology Ltd., the two companies have submitted a new drug application to the Food and Drug Administration for evaluating a transmucosal drug delivery technology in human clinical trials. Designed to provide rapid delivery of a potent opiate, the companies expect the technology to be used for quick relief or with compounds that are rapidly broken down in the body when taken orally.
Atrix Laboratories Inc. (Nasdaq: ATRX), a Fort Collins-based pharmaceutical company, has formed a joint venture with Elan Corp. (NYSE: ELN) to advance the testing of a new pain product for cancer patients. Through their collaborative effort, Transmucosal Technology Ltd., the two companies have submitted a new drug application to the Food and Drug Administration for evaluating a transmucosal drug delivery technology in human clinical trials. Designed to provide rapid delivery of a potent opiate, the companies expect the technology to be used for quick relief or with compounds that are rapidly broken down in the body when taken orally.
SPONSORED CONTENT